411 related articles for article (PubMed ID: 11460031)
1. [Immunotherapy for melanoma: how can tolerance be overcome?].
Robert C
Ann Dermatol Venereol; 2001; 128(6-7):709-13. PubMed ID: 11460031
[No Abstract] [Full Text] [Related]
2. Self-recognition and tumor response to immunotherapy.
Ernstoff MS
J Clin Oncol; 2005 Sep; 23(25):5875-7. PubMed ID: 16087939
[No Abstract] [Full Text] [Related]
3. Immunotherapy of melanoma.
Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
[TBL] [Abstract][Full Text] [Related]
4. [Advances in cellular immunotherapy for malignant melanoma].
López M; Escobar A; Alfaro J; Fodor M; Larrondo M; Ferrada C; Salazar-Onfray F
Rev Med Chil; 2004 Sep; 132(9):1115-26. PubMed ID: 15543770
[TBL] [Abstract][Full Text] [Related]
5. The unfulfilled promise of melanoma vaccines.
Livingston P
Clin Cancer Res; 2001 Jul; 7(7):1837-8. PubMed ID: 11448892
[No Abstract] [Full Text] [Related]
6. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; Liénard D; Lejeune F; Cerottini JC; Romero P
Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165
[TBL] [Abstract][Full Text] [Related]
7. [Cytotoxic T-cell immune response against melanoma antigens].
Ayyoub M
Ann Dermatol Venereol; 1998 Nov; 125 Suppl 2():S34-6. PubMed ID: 9922891
[No Abstract] [Full Text] [Related]
8. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.
Hsueh EC; Morton DL
Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158
[TBL] [Abstract][Full Text] [Related]
9. Melanoma antigens and targets for vaccination.
Kang N; Truman H; Sanders R; Kupsch J
Br J Hosp Med; 1997 Sep 17-30; 58(6):282-6. PubMed ID: 9488805
[TBL] [Abstract][Full Text] [Related]
10. Immunology and immunotherapy of human malignant melanoma.
Bystryn JC
Dermatol Clin; 1985 Apr; 3(2):327-34. PubMed ID: 2937585
[TBL] [Abstract][Full Text] [Related]
11. T-cell-based immunotherapy of melanoma: what have we learned and how can we improve?
Campoli M; Ferrone S
Expert Rev Vaccines; 2004 Apr; 3(2):171-87. PubMed ID: 15056043
[TBL] [Abstract][Full Text] [Related]
12. Cancer. Cancer immunotherapy is more than a numbers game.
Offringa R
Science; 2006 Oct; 314(5796):68-9. PubMed ID: 17023641
[No Abstract] [Full Text] [Related]
13. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for advanced melanoma: Current knowledge and future directions.
Nakamura K; Okuyama R
J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of melanoma: the good news, the bad ones and what to do next.
Marincola FM; Ferrone S
Semin Cancer Biol; 2003 Dec; 13(6):387-9. PubMed ID: 15001156
[No Abstract] [Full Text] [Related]
16. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
17. [Active specific immunotherapy of malignant melanoma].
Lotem M; Shiloni E; Ingber A; Peretz T
Harefuah; 1997 Aug; 133(3-4):122-6. PubMed ID: 9332080
[No Abstract] [Full Text] [Related]
18. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?
Sondak VK; Sabel MS; Mulé JJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2337s-2341s. PubMed ID: 16609055
[TBL] [Abstract][Full Text] [Related]
19. [General principles and first clinical trials of therapeutic vaccines against cancer].
Baurain JF; Van der Bruggen P; Van den Eynde BJ; Coulie PG; Van Baren N
Bull Cancer; 2008 Mar; 95(3):327-35. PubMed ID: 18390413
[TBL] [Abstract][Full Text] [Related]
20. Special report: vaccines for the treatment of malignant melanoma.
Tecnologica MAP Suppl; 2001 Apr; ():19-20. PubMed ID: 11718143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
